After nonfatal myocardial infarction or stroke, initiation of a GLP-1 receptor agonist was linked to reduced risk for all-cause and CV-related mortality in patients with diabetes, researchers reported ...

Sotagliflozin, a dual SGLT1/2 inhibitor, shows benefit specifically for reducing myocardial infarction and stroke risks. Among patients with type 2 diabetes and chronic kidney disease (CKD) at ...

The proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, ...

Some patients with an acute large-vessel ischemic stroke who already show a large-core infarct at early imaging can still benefit from thrombectomy, especially if the procedure successfully restores ...

WASHINGTON, DC – OCTOBER 29, 2024 – The largest trial to examine the impact of colchicine in acute myocardial infarction (MI) found that both acute and long-term colchicine use did not reduce ...

Heart attack patients who do not take daily aspirin have an elevated likelihood of recurrent myocardial infarction, stroke or death compared with those who consistently take the drug, according to ...

An episode of shingles, caused by the herpes zoster virus, temporarily increases the risk for stroke and potentially myocardial infarction (MI) in the months after the infection, according to two ...

The artery of Percheron (AOP) represents a rare anatomical variant whereby a single arterial trunk supplies both paramedian thalami and, in many cases, the rostral midbrain. Occlusion of this artery ...

A boxed warning for testosterone on major adverse cardiovascular events is out and a new blood pressure warning is in, the FDA announced late last week as part of a class-wide labeling update for all ...